低滴度的母体抗体既能增强也能抑制B细胞对组合的减毒活人类轮状病毒和病毒样颗粒-免疫刺激复合物疫苗的反应。
Low titer maternal antibodies can both enhance and suppress B cell responses to a combined live attenuated human rotavirus and VLP-ISCOM vaccine.
作者信息
Nguyen Trang V, Yuan Lijuan, Azevedo Marli S P, Jeong Kwang-Il, Gonzalez Ana M, Iosef Cristiana, Lovgren-Bengtsson Karin, Morein Bror, Lewis Peggy, Saif Linda J
机构信息
Food Animal Health Research Program, Department of Veterinary Preventive Medicine, Ohio Agricultural Research and Development Center, The Ohio State University, 1680 Madison Avenue, Wooster, OH 44691-4096, USA.
出版信息
Vaccine. 2006 Mar 20;24(13):2302-16. doi: 10.1016/j.vaccine.2005.11.043. Epub 2005 Dec 1.
We investigated effects of low titer (Lo) circulating MatAb on protection and immunogenicity of attenuated (Att) human rotavirus (HRV) priming and 2/6-virus-like particle (VLP)-immunostimulating complex (ISCOM) boosting (AttHRV/VLP) or VLP-ISCOM alone vaccines. LoMatAb had both enhancing and suppressing effects on B cell responses, depending on tissue, antibody isotype and vaccine. Differential effects of LoMatAb on IgA responses in different tissues suggest that LoMatAb did not suppress induction of IgA effector and memory B cells but impaired homing of these cells to secondary lymphoid or effector tissues, reducing IgA antibody secreting cells and antibodies at these sites. The AttHRV/VLP vaccine partially overcame LoMatAb suppression, conferred moderate protection against virulent HRV (as measured by reduced viral shedding and diarrhea) and represents a new candidate for rotavirus vaccines for both humans and animals.
我们研究了低滴度（Lo）循环母源抗体（MatAb）对减毒（Att）人轮状病毒（HRV）初免以及2/6病毒样颗粒（VLP）-免疫刺激复合物（ISCOM）加强免疫（AttHRV/VLP）或单独VLP-ISCOM疫苗的保护作用和免疫原性的影响。LoMatAb对B细胞反应具有增强和抑制作用，这取决于组织、抗体亚型和疫苗。LoMatAb对不同组织中IgA反应的不同影响表明，LoMatAb并未抑制IgA效应B细胞和记忆B细胞的诱导，但损害了这些细胞归巢至次级淋巴组织或效应组织，减少了这些部位的IgA抗体分泌细胞和抗体。AttHRV/VLP疫苗部分克服了LoMatAb的抑制作用，对强毒HRV提供了适度的保护（通过减少病毒排泄和腹泻来衡量），是一种用于人类和动物的新型轮状病毒疫苗候选物。
Zotero 插件